

10/513699

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances

<12/04/2007>

Erich Leese

10/513699

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:01:03 ON 18 JAN 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 18 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2008 HIGHEST RN 1000264-70-9
DICTIONARY FILE UPDATES: 17 JAN 2008 HIGHEST RN 1000264-70-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>



=>

Uploading C:\Program Files\Stnexp\Queries\10596851.str

<12/04/2007>

Erich Leese

10/513699



chain nodes :
19 20 21 22 23 24 25 26 27 28 29 30 31 32 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
3-21 6-31 8-31 12-27 13-34 16-31 19-22 19-20 20-21 20-24 21-32 23-24
25-26 26-27 26-29 27-30 28-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
exact/norm bonds :
12-27 13-14 13-18 13-34 14-15 15-16 16-17 16-31 17-18 19-20 20-21 20-24
21-32 25-26 26-27 26-29 27-30 28-29
exact bonds :
3-21 6-31 8-31 19-22 23-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 : 13 :

G1:Cb,Ak

G2:H,Cb,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 34:CLASS

<12/04/2007>

Erich Leese

10/513699

L1 STRUCTURE UPLOADED

=> s l1 full

FULL SEARCH INITIATED 15:02:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 203 TO ITERATE

100.0% PROCESSED 203 ITERATIONS

90 ANSWERS

SEARCH TIME: 00.00.01

L2 90 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.82

179.03

FILE 'CAPLUS' ENTERED AT 15:02:19 ON 18 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jan 2008 VOL 148 ISS 4

FILE LAST UPDATED: 17 Jan 2008 (20080117/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2 full

L3 2 L2

=> d ibib abs hitstr tot

<12/04/2007>

Erich Leese

10/513699

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:638860 CAPLUS

DOCUMENT NUMBER: 143:153402

TITLE: Preparation of diarylmethylpiperazines as δ receptor ligands for the treatment of pain

INVENTOR(S): Brown, William; Griffin, Andrew

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066148	A1	20050721	WO 2005-SE14	20050105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005204010	A1	20050721	AU 2005-204010	20050105
CA 2552851	A1	20050721	CA 2005-2552851	20050105
EP 1706393	A1	20061004	EP 2005-704688	20050105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1926122	A	20070307	CN 2005-80006254	20050105
BR 2005006702	A	20070502	BR 2005-6702	20050105
JP 2007517873	T	20070705	JP 2006-549190	20050105
IN 2006DN03738	A	20070420	IN 2006-DN3738	20060629
MX 2006PA07664	A	20060904	MX 2006-PA7664	20060703
NO 2006003619	A	20061009	NO 2006-3619	20060809
US 2007293502	A1	20071220	US 2007-596851	20070529
PRIORITY APPLN. INFO.:			SE 2004-27	A 20040109
			WO 2005-SE14	W 20050105

OTHER SOURCE(S): CASREACT 143:153402; MARPAT 143:153402

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = alkyl, alkenyl, cycloalkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3 = alkyl, cycloalkyl] and their pharmaceutically acceptable salts were prepared For example, N-alkylation of piperazine II (R1 =H) with bromoethyl Me ether afforded the hCL salt of claimed diarylmethylpiperazine II (R1 = CH2CH2OCH3) in 68% yield. In human δ receptor assays, certain examples of compds. I exhibited IC50 values ranging from 0.2-3.7 nM, with an average of 1 nM (sic).

10/513699

IT 859634-99-4P 859635-00-0P 859635-01-1P
859635-02-2P 859635-03-3P 859635-04-4P
859635-05-5P 859635-06-6P 859635-07-7P
859635-08-8P 859635-09-9P 859635-10-2P
859635-11-3P 859635-12-4P 859635-13-5P
859635-14-6P 859635-15-7P 859635-16-8P
859635-17-9P 859635-18-0P 859843-90-6P
859843-91-7P 859843-92-8P 859843-93-9P
859843-94-0P 859843-95-1P 859843-96-2P
859843-97-3P 859843-98-4P 859843-99-5P
859844-00-1P 859844-01-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylmethylpiperazines as δ receptor ligands for treatment of pain)

RN 859634-99-4 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 859635-00-0 CAPLUS

CN Carbamic acid, [3-[(S)-(4-butyl-1-piperazinyl)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/513699



RN 859635-01-1 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 859635-02-2 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/513699



RN 859635-03-3 CAPLUS

CN Carbamic acid, [3-[(S)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 859635-04-4 CAPLUS

CN Carbamic acid, [3-[(S)-[4-(cyclobutylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/513699



RN 859635-05-5 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 859635-06-6 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-ethoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10/513699




● HCl

RN 859635-07-7 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-methoxypropyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 859635-08-8 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-propyl-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 859635-09-9 CAPLUS

CN Carbamic acid, [3-[(R)-(4-butyl-1-piperazinyl)][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 859635-10-2 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 859635-11-3 CAPLUS

CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 859635-12-4 CAPLUS

CN Carbamic acid, [3-[(R)-[4-(cyclobutylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 859635-13-5 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 859635-14-6 CAPLUS

CN Carbamic acid, [3-[(R)-(4-butyl-1-piperazinyl)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 859635-15-7 CAPLUS

CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 859635-16-8 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 859635-17-9 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-ethyl-1-piperazinyl)methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859635-18-0 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-methyl-1-piperazinyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 859843-90-6 CAPLUS

CN Carbamic acid, [3-[(S)-(4-butyl-1-piperazinyl)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 859843-91-7 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/513699



● HCl

RN 859843-92-8 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl


RN 859843-93-9 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese

10/513699


Absolute stereochemistry. Rotation (-).



● HCl

RN 859843-94-0 CAPLUS
CN Carbamic acid, [3-[(R)-(4-butyl-1-piperazinyl)][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859843-95-1 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



● HCl

RN 859843-96-2 CAPLUS
CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859843-97-3 CAPLUS
CN Carbamic acid, [3-[(R)-[4-(cyclobutylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



● HCl

RN 859843-98-4 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859843-99-5 CAPLUS
CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10/513699




● HCl

RN 859844-00-1 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 859844-01-2 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-methyl-1-piperazinyl)methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



● HCl

IT 859635-21-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diarylmethylpiperazines as δ receptor ligands for treatment of pain)
RN 859635-21-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(S)-[4-[(diethylamino)carbonyl]phenyl][3-[(methoxycarbonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

<12/04/2007>

Erich Leese

10/513699

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:412932 CAPLUS

DOCUMENT NUMBER: 140:423709

TITLE: Preparation of N-[4-(phenylpiperazinylmethyl)phenyl]carbamates for treatment of pain, anxiety, or gastrointestinal disorders

INVENTOR(S): Brown, William; Griffin, Andrew; Jones, Paul; Page, Daniel; Plobeck, Niklas; Walpole, Christopher

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004041802	A1	20040521	WO 2003-SE1707	20031105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502732	A1	20040521	CA 2003-2502732	20031105
AU 2003278665	A1	20040607	AU 2003-278665	20031105
EP 1562924	A1	20050817	EP 2003-770198	20031105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015995	A	20050927	BR 2003-15995	20031105
CN 1711252	A	20051221	CN 2003-80102831	20031105
JP 2006514002	T	20060427	JP 2004-549776	20031105
NZ 539484	A	20070531	NZ 2003-539484	20031105
IN 2005DN01579	A	20061229	IN 2005-DN1579	20050419
MX 2005PA04708	A	20050803	MX 2005-PA4708	20050502
US 2006122193	A1	20060608	US 2005-533654	20050504
US 7253173	B2	20070807		
ZA 2005003556	A	20060830	ZA 2005-3556	20050504
NO 2005002698	A	20050606	NO 2005-2698	20050606
US 2007254890	A1	20071101	US 2007-774935	20070709
PRIORITY APPLN. INFO.:			SE 2002-3303	A 20021107
			WO 2003-SE1707	W 20031105
			US 2005-533654	A1 20050504
OTHER SOURCE(S):	MARPAT 140:423709			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein R1 = (un)substituted (hetero)aryl(alkyl); R2 and

<12/04/2007>

Erich Leese

R3 = independently H or (un)substituted (cyclo)alkyl; or pharmaceutically acceptable salts, diastereomers, enantiomers, or mixts. thereof] were prepared as opioid δ receptor ligands. For example, 4-carboxybenzaldehyde was amidated with diethylamine using SOCl₂ in CH₂Cl₂ to give N,N-diethyl-4-formylbenzamide (90%). Coupling of the amide with N-Boc-piperazine in the presence of benzotriazole in toluene, followed by reaction with 3-bromophenylzinc iodide in THF, afforded tert-Bu 4-[(3-bromophenyl)[4-[(diethylamino)carbonyl]phenyl]methyl]-1-piperazinecarboxylate (33%). Coupling with Me carbamate (62%) using xantphos, Cs₂CO₃, and Pd₂(dba)₃ in dioxane, deprotection (89%) with TFA in CH₂Cl₂, and chiral HPLC separation of the enantiomers provided (-)-[3-[[4-[(diethylamino)carbonyl]phenyl]-1-piperazinylmethyl]phenyl]carbamate Me ester. Reaction of the piperazine with benzaldehyde in the presence of NaBH(OAc)₃ in CH₂Cl₂ gave (R)-II. In binding assays using human 293S cells expressing cloned human opioid receptors and neomycin resistance, (R)-II and ten other exemplified compds. exhibited strong binding to the δ receptor with IC₅₀ values in the range of 0.25-0.74 nM and showed some activity toward the κ (IC₅₀ = 247-1636 nM) and μ (IC₅₀ = 93-1100 nM) receptors. In functional assays, (R)-II demonstrated δ receptor agonist activity by activating the binding of GTP to G-proteins. Thus, I and their pharmaceutical compns. are useful in therapy, in particular for the treatment of gastrointestinal disorders, anxiety, or pain (no data).

IT 691890-43-4P, 4-[[4-[(Diethylamino)carbonyl]phenyl][3-[(methoxycarbonyl)amino]phenyl]methyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of N-[(phenylpiperazinylmethyl)phenyl]carbamates as δ receptor agonists for treatment of pain, anxiety, or gastrointestinal disorders)
 RN 691890-43-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-[(diethylamino)carbonyl]phenyl][3-[(methoxycarbonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 691890-67-2P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (δ receptor agonist; preparation of N-[(phenylpiperazinylmethyl)phenyl


10/513699

]carbamates as δ receptor agonists for treatment of pain,
anxiety, or gastrointestinal disorders)

RN 691890-67-2 CAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]methyl-, methyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT 691890-72-9P 691890-74-1P 691890-76-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(δ receptor agonist; preparation of N-[(phenylpiperazinylmethyl)phenyl]
]carbamates as δ receptor agonists for treatment of pain,
anxiety, or gastrointestinal disorders)

RN 691890-72-9 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:9) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-71-8

CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (+).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-74-1 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:13) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-73-0

CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (-).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-76-3 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 691890-75-2

CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (+).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 691890-51-4P, (R)-Methyl [3-[[4-[(diethylamino)carbonyl]phenyl](4-benzylpiperazin-1-yl)methyl]phenyl]carbamate 691890-52-5P, (S)-Methyl [3-[[4-[(diethylamino)carbonyl]phenyl](4-benzylpiperazin-1-yl)methyl]phenyl]carbamate 691890-53-6P 691890-54-7P 691890-55-8P 691890-56-9P 691890-57-0P 691890-58-1P 691890-59-2P 691890-60-5P 691890-61-6P 691890-62-7P 691890-63-8P 691890-64-9P 691890-65-0P 691890-66-1P 691890-68-3P 691890-69-4P 691890-70-7P 691890-71-8P 691890-73-0P 691890-75-2P 691890-77-4P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl](4-benzylpiperazin-1-yl)methyl]phenyl]carbamate 691890-78-5P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(thien-2-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-79-6P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(thien-3-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-80-9P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(2-furylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-81-0P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(3-furylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-82-1P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-83-2P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(pyridin-2-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-84-3P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-85-4P, Methyl

10/513699

[3-[[4-[(diethylamino)carbonyl]phenyl][4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-86-5P 691890-87-6P
691890-88-7P 691890-89-8P 691890-90-1P
691890-91-2P 691890-92-3P 691890-93-4P
691890-94-5P 691890-95-6P 691890-96-7P
691890-97-8P 691890-98-9P 691890-99-0P
691891-00-6P 691891-01-7P 691891-02-8P
691891-03-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(δ receptor agonist; preparation of N-[(phenylpiperazinylmethyl)phenyl]carbamates as δ receptor agonists for treatment of pain, anxiety, or gastrointestinal disorders)

RN 691890-51-4 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 691890-52-5 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/513699



RN 691890-53-6 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 691890-54-7 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 691890-55-8 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 691890-56-9 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 691890-57-0 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 691890-58-1 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 691890-59-2 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 691890-60-5 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 691890-61-6 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 691890-62-7 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/513699



RN 691890-63-8 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 691890-64-9 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/513699



RN 691890-65-0 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 691890-66-1 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


10/513699



RN 691890-68-3 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 691890-69-4 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/513699



RN 691890-70-7 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 691890-71-8 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/513699



RN 691890-73-0 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 691890-75-2 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

10/513699




RN 691890-77-4 CAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-78-5 CAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 691890-79-6 CAPLUS

<12/04/2007>

Erich Leese


10/513699

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-80-9 CAPLUS


CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-81-0 CAPLUS


CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

10/513699



RN 691890-82-1 CAPLUS


CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-83-2 CAPLUS


CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

10/513699




RN 691890-84-3 CAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-85-4 CAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-86-5 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:21) (9CI) (CA INDEX NAME)


10/513699

CM 1

CRN 691890-51-4

CMF C31 H38 N4 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-87-6 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:8) (9CI)
(CA INDEX NAME)


CM 1

CRN 691890-52-5

CMF C31 H38 N4 O3


Absolute stereochemistry. Rotation (+).

10/513699



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691890-88-7 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:7) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-53-6
CMF C29 H36 N4 O3 S

Absolute stereochemistry. Rotation (+).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-89-8 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-54-7

CMF C29 H36 N4 O3 S

Absolute stereochemistry. Rotation (-).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-90-1 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-55-8

CMF C29 H36 N4 O3 S

Absolute stereochemistry. Rotation (+).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-91-2 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:7) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-56-9

CMF C29 H36 N4 O3 S

Absolute stereochemistry. Rotation (-).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-92-3 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-57-0

CMF C29 H36 N4 O4

Absolute stereochemistry. Rotation (+).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-93-4 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:8) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-58-1

CMF C29 H36 N4 O4

Absolute stereochemistry. Rotation (-).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-94-5 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-59-2

CMF C29 H36 N4 O4

Absolute stereochemistry. Rotation (+).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-95-6 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:21) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-61-6

CMF C28 H36 N6 O3

Absolute stereochemistry. Rotation (-).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-96-7 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-62-7

CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (+).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-97-8 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-63-8

CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (-).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-98-9 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:19) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-64-9

CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (+).


10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-99-0 CAPLUS

CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:13) (9CI) (CA INDEX NAME)


CM 1

CRN 691890-65-0

CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (-).


10/513699



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 691891-00-6 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, hydrochloride (10:29) (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●29/10 HCl

<12/04/2007>


Erich Leese

10/513699

RN 691891-01-7 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, hydrochloride (2:3) (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●3/2 HCl

RN 691891-02-8 CAPLUS


CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 691890-70-7

CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (-).




<12/04/2007>

Erich Leese

10/513699

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 691891-03-9 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 691890-60-5
CMF C29 H36 N4 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



10/513699

<12/04/2007>

Erich Leese

10/513699

=> d his

(FILE 'HOME' ENTERED AT 15:01:03 ON 18 JAN 2008)

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 18 JAN 2008

L1 STRUCTURE UPLOADED

L2 90 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:02:19 ON 18 JAN 2008

L3 2 S L2 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

12.82

191.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.60

-1.60

STN INTERNATIONAL LOGOFF AT 15:04:33 ON 18 JAN 2008